Table 1.
Gene expression profile assays in early-stage breast cancer study characteristics
| Study | Country | Patients | FUa | LN status | ER | Treatment |
|---|---|---|---|---|---|---|
| Ahr-1 | Germany | 27 | 2.0 | Positive | Mixed | Unknown |
| Ahr-2 | Germany | 20 | 2.0 | Negative | Mixed | Unknown |
| Bertucci | France | 55 | 5.0 | Both | Mixed | Chemotherapy |
| Huang | USA | 52 | 3.0 | Both | Mixed | Unknown |
| Iwao | Japan | 119 | 4.5 | Both | Mixed | Unknown |
| Paik | USA | 668 | 14.0 | Negative | Positive | Tamoxifen |
| Esteva | USA | 149 | 10.0 | Negative | Mixed | None |
| van De Vijver-1 | The Netherlands | 78 | 7.8 | Negative | Mixed | Mixed |
| van De Vijver-2 | The Netherlands | 67 | 7.8 | Negative | Mixed | Mixed |
| van De Vijver-3 | The Netherlands | 114 | 7.8 | Positive | Mixed | Mixed |
| Wang | The Netherlands | 171 | 5.0 | Negative | Mixed | None |
a
Follow-up in years.
Abbreviations: ER, estrogen receptor; LN, lymph node.